Our drugs activate self-healing processes in neurologic diseases. Our lead drug IPL344 had unparalleled clinical results in an open label phase 2 study in ALS.
Only investors on Gust who have been granted access can view this content.
Interested in this startup? Sign In or Sign Up to request more information.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.
Get Started for Free